286 related articles for article (PubMed ID: 8013286)
1. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma.
Mayol RF; Cole CA; Luke GM; Colson KL; Kerns EH
Drug Metab Dispos; 1994; 22(2):304-11. PubMed ID: 8013286
[TBL] [Abstract][Full Text] [Related]
2. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
3. Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms.
Li AC; Shou WZ; Mai TT; Jiang XY
Rapid Commun Mass Spectrom; 2007; 21(24):4001-8. PubMed ID: 18000840
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.
Shukla UA; Marathe PH; Pittman KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):502-7. PubMed ID: 8100508
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the antianxiety drug buspirone in human subjects.
Jajoo HK; Mayol RF; LaBudde JA; Blair IA
Drug Metab Dispos; 1989; 17(6):634-40. PubMed ID: 2575499
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis.
Barbhaiya RH; Shukla UA; Natarajan CS; Behr DA; Greene DS; Sainati SM
Clin Pharmacol Ther; 1995 Oct; 58(4):390-8. PubMed ID: 7586930
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects.
Jajoo HK; Mayol RF; LaBudde JA; Blair IA
Drug Metab Dispos; 1990; 18(1):28-35. PubMed ID: 1970774
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
Barbhaiya RH; Dandekar KA; Greene DS
Drug Metab Dispos; 1996 Jan; 24(1):91-5. PubMed ID: 8825195
[TBL] [Abstract][Full Text] [Related]
9. Structure elucidation of three isomeric metabolites of SYN-2836, a novel antifungal agent, in dogs via liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry methodologies.
Bu HZ; Poglod M; Micetich RG; Khan JK
J Mass Spectrom; 1999 Nov; 34(11):1185-94. PubMed ID: 10548812
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the antipsychotic drug tiospirone in humans.
Mayol RF; Jajoo HK; Klunk LJ; Blair IA
Drug Metab Dispos; 1991; 19(2):394-9. PubMed ID: 1676643
[TBL] [Abstract][Full Text] [Related]
11. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD
Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation of pravastatin sodium in humans.
Everett DW; Chando TJ; Didonato GC; Singhvi SM; Pan HY; Weinstein SH
Drug Metab Dispos; 1991; 19(4):740-8. PubMed ID: 1680649
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantitation of d7-nefazodone, nefazodone, d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry.
Yao M; Srinivas NR
Biomed Chromatogr; 2000 Apr; 14(2):106-12. PubMed ID: 10694704
[TBL] [Abstract][Full Text] [Related]
15. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of bepridil in laboratory animals and humans.
Wu WN; Hills JF; Chang SY; Ng KT
Drug Metab Dispos; 1988; 16(1):69-77. PubMed ID: 2894958
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2 (1H)-one (L-696,229), an HIV-1 reverse transcriptase inhibitor, by rat liver slices and in humans.
Balani SK; Kauffman LR; Arison BH; Olah TV; Goldman ME; Varga SL; O'Brien JA; Ramjit HG; Rooney CS; Hoffman JM
Drug Metab Dispos; 1994; 22(2):200-5. PubMed ID: 7516852
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation and elimination of 14C-flecainide acetate in humans.
McQuinn RL; Quarfoth GJ; Johnson JD; Banitt EH; Pathre SV; Chang SF; Ober RE; Conard GJ
Drug Metab Dispos; 1984; 12(4):414-20. PubMed ID: 6148206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
